ArticleAnnals of surgical oncology2025
Surgery for Retroperitoneal Soft Tissue Sarcoma is Safe Following Multimodal Treatment with Regional Hyperthermia.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Modelling Morbidity in Retroperitoneal Sarcoma-Multimodal Therapy is Safe While Surgery Sets the Tone.Annals of surgical oncology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultimodal treatment has been suggested to improve outcomes in retroperitoneal soft tissue sarcoma (RPS). This study assessed the impact of neoadjuvant radiotherapy, chemotherapy, and the combination with regional hyperthermia (RHT) on postoperative morbidity using the Comprehensive Complication Index (CCI). PATIENTS AND
methodsThis single-center retrospective cohort study analyzed 335 surgeries for primary and recurrent RPS (2009-2022). The primary outcome was CCI, which was modeled using zero-one inflated beta regression. Predictors included age, sex, recurrence, transfusion needs, and the number of resected organs.
resultsPatients with neoadjuvant radiotherapy (CCI, 32.79 ± 25.24 vs 22.76 ± 26.75), neoadjuvant chemotherapy (28.06 ± 24.35 vs 23.55 ± 27.75), and the combination of neoadjuvant chemotherapy + RHT (31.52 ± 25.78 vs 22.54 ± 26.42) had higher CCI scores compared with patients without these treatments. In multivariable models of the probability of a complication (CCI > 0) or of the severity (0 < CCI < 100) these neoadjuvant treatments did not significantly influence CCI. The resection of > 3 organs was associated with more frequent (p = 0.004) and more severe (p = 0.002) complications, as were blood transfusions (CCI > 0, p = 0.030; 0 < CCI < 100, p = 0.034). When the interaction between therapy and recurrence was added to these models, the combination of radiotherapy and chemotherapy (without RHT, n = 7) was associated with higher morbidity, whereas all other protocols appeared to be equally safe in primary and recurrent cases.
conclusionsPostoperative morbidity is driven by surgical factors, particularly transfusions and multivisceral resections, rather than multimodal neoadjuvant therapies. Intensive protocols, including RHT, are safe for patients with RPS from a surgical perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.